Key Insights on Johnson & Johnson's Dividend Ahead of May 27, 2025 Ex-Dividend Date
Generado por agente de IAAinvest Dividend Digest
viernes, 23 de mayo de 2025, 10:12 pm ET1 min de lectura
JNJ--
Johnson & Johnson (JNJ) has announced a forthcoming dividend of $1.300 per share, with an ex-dividend date set for May 27, 2025, and a payment date on Jun 10, 2025. This amount is notably higher compared to the average of the last ten dividends, which stands at approximately $0.456. The announcement was made on Apr 15, 2025. The last dividend issued by the company on Mar 4, 2025, was $1.240 per share. The consistent increase in dividend payouts reflects the company's strong financial health and commitment to returning value to shareholders.
Recently, Johnson & JohnsonJNJ-- has been actively engaged in several significant initiatives. The company expanded its efforts to support the global nursing workforce through the new social impact platform, J&JJNJ-- CareCommunity. In the area of cancer research, promising new data was unveiled from its portfolio concerning hematologic malignancies and solid tumors, marking a significant step in innovative cancer treatments. Additionally, Johnson & Johnson MedTechMED-- announced the U.S. launch of the SOUNDSTAR CRYSTAL™ Ultrasound Catheter, a device designed to enhance intracardiac echocardiography imaging in cardiac ablation procedures. This development underscores the company's commitment to advancing medical technology and improving patient outcomes.
Over the past week, Johnson & Johnson has also been in the spotlight due to a favorable vote from the FDA's Oncologic Drugs Advisory Committee for its product DARZALEX FASPRO®, aimed at treating high-risk conditions. Amid these developments, the company's stock experienced a slight decline, closing at $152.51, representing a -0.44% adjustment from the previous day's close. However, analysts maintain a positive outlook, with a consensus rating of Moderate Buy and an average price target of $169.50, implying an upside potential.
In conclusion, Johnson & Johnson's recent strategic moves and robust dividend policy highlight its stable financial performance and innovative prowess. Investors should note that May 27, 2025, is the ex-dividend date, the last opportunity to purchase shares and receive the upcoming dividend. Any acquisitions after this date will not qualify for the current dividend payout.
Recently, Johnson & JohnsonJNJ-- has been actively engaged in several significant initiatives. The company expanded its efforts to support the global nursing workforce through the new social impact platform, J&JJNJ-- CareCommunity. In the area of cancer research, promising new data was unveiled from its portfolio concerning hematologic malignancies and solid tumors, marking a significant step in innovative cancer treatments. Additionally, Johnson & Johnson MedTechMED-- announced the U.S. launch of the SOUNDSTAR CRYSTAL™ Ultrasound Catheter, a device designed to enhance intracardiac echocardiography imaging in cardiac ablation procedures. This development underscores the company's commitment to advancing medical technology and improving patient outcomes.
Over the past week, Johnson & Johnson has also been in the spotlight due to a favorable vote from the FDA's Oncologic Drugs Advisory Committee for its product DARZALEX FASPRO®, aimed at treating high-risk conditions. Amid these developments, the company's stock experienced a slight decline, closing at $152.51, representing a -0.44% adjustment from the previous day's close. However, analysts maintain a positive outlook, with a consensus rating of Moderate Buy and an average price target of $169.50, implying an upside potential.
In conclusion, Johnson & Johnson's recent strategic moves and robust dividend policy highlight its stable financial performance and innovative prowess. Investors should note that May 27, 2025, is the ex-dividend date, the last opportunity to purchase shares and receive the upcoming dividend. Any acquisitions after this date will not qualify for the current dividend payout.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios